Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

11 / 39

2nd vs. 1 st Generation ALK TKI
Peters – NEJM 2018 * Camidge – NEJM 2018 * Popat – ESMO 2018
ALTA1L TRIAL ALEX TRIAL
23%
~12%
Brigatinib vs. Crizotinib. Brain MRI/8w Alectinib vs . Crizotinib. . Brain MRI/8w
icRR (N=43): 81% vs. 50%
ORR (N=303): 83% vs. 76%
icRR (N=39): 78% vs. 29%
ORR (N=275): 76% vs . 73%
Time to symptomatic brain PD?